Vukovic N, Van Elsas A, Verbeek JS, Zaiss DMW (2021)
Publication Type: Journal article, Review article
Publication year: 2021
Book Volume: 203
Pages Range: 351-365
Journal Issue: 3
DOI: 10.1111/cei.13545
The clinical application of monoclonal antibodies (mAbs) has revolutionized the field of cancer therapy, as it has enabled the successful treatment of previously untreatable types of cancer. Different mechanisms play a role in the anti-tumour effect of mAbs. These include blocking of tumour-specific growth factor receptors or of immune modulatory molecules as well as complement and cell-mediated tumour cell lysis. Thus, for many mAbs, Fc-mediated effector functions critically contribute to the efficacy of treatment. As immunoglobulin (Ig) isotypes differ in their ability to bind to Fc receptors on immune cells as well as in their ability to activate complement, they differ in the immune responses they activate. Therefore, the choice of antibody isotype for therapeutic mAbs is dictated by its intended mechanism of action. Considering that clinical efficacy of many mAbs is currently achieved only in subsets of patients, optimal isotype selection and Fc optimization during antibody development may represent an important step towards improved patient outcome. Here, we discuss the current knowledge of the therapeutic effector functions of different isotypes and Fc-engineering strategies to improve mAbs application.
APA:
Vukovic, N., Van Elsas, A., Verbeek, J.S., & Zaiss, D.M.W. (2021). Isotype selection for antibody-based cancer therapy. Clinical and Experimental Immunology, 203(3), 351-365. https://doi.org/10.1111/cei.13545
MLA:
Vukovic, Natasa, et al. "Isotype selection for antibody-based cancer therapy." Clinical and Experimental Immunology 203.3 (2021): 351-365.
BibTeX: Download